March 07, 2014
A Massachusetts federal judge on Friday requested further briefing on whether he should reconsider portions of an order that granted victories to drugmakers Ranbaxy Inc. and Teva Pharmaceutical Industries Ltd. in a pay-for-delay class action involving the heartburn drug Nexium.
March 03, 2014
New evidence from the U.S. Food and Drug Administration shows that Ranbaxy Inc. could have received approval for a generic version of heartburn drug Nexium far sooner than it did, direct purchasers told a Massachusetts federal judge on Friday in a bid to revive their pay-for-delay suit against the drugmaker.
January 14, 2014
AstraZeneca PLC couldn't convince a Massachusetts federal judge to shave several chain pharmacies' claims from multidistrict litigation alleging the company delayed the entry of generic Nexium, with the court on Monday rejecting AstraZeneca's argument that the retailers couldn't prove they suffered any injury.
December 11, 2013
A Massachusetts judge granted class certification on Wednesday to a group of direct purchasers alleging AstraZeneca PLC and others breached antitrust laws by engineering the delay of a generic form of heartburn drug Nexium.
November 27, 2013
A Massachusetts federal judge on Wednesday rejected AstraZeneca PLC and Ranbaxy Inc.'s bid to dismiss as time-barred certain claims in multidistrict litigation alleging the companies violated antitrust laws by agreeing to delay entry of a generic version of AstraZeneca's heartburn drug Nexium.
November 14, 2013
A Massachusetts federal judge certified a class of Nexium end-buyers on Thursday who accused AstraZeneca PLC and others of violating antitrust laws by delaying a generic version of AstraZeneca's heartburn drug, ruling the class met adequacy and predominance requirements.
October 16, 2013
AstraZeneca PLC and Ranbaxy Inc. filed for partial summary judgment Tuesday in multidistrict litigation alleging the companies violated antitrust laws by agreeing to delay entry of a generic version of AstraZeneca's heartburn drug Nexium, saying a four-year statute of limitations on some claims has run out.
September 17, 2013
AstraZeneca PLC and several generic-drug makers facing multidistrict antitrust litigation alleging they unlawfully delayed the market entry of a generic form of Nexium told a Massachusetts federal judge Monday that a "sprawling class" of the drug's third-party purchasers should not be certified in light of the Supreme Court's Wal-Mart Stores Inc. v. Dukes decision.
September 12, 2013
A Massachusetts federal judge Wednesday largely kept intact multidistrict litigation brought by direct- and third-party purchasers that allege AstraZeneca PLC and several generic-drug makers violated antitrust laws by entering into agreements to delay entry of a generic version of AstraZeneca's heartburn drug Nexium.
January 25, 2013
The Massachusetts federal judge handling multidistrict litigation over whether AstraZeneca PLC illegally delayed generic versions of its heartburn drug Nexium scolded plaintiffs' attorneys Thursday, using strong words to criticize a fight over who gets to be lead counsel.